United States Of America was Legend Biotech’s largest region in fiscal 2024, bringing in $434.71M of $482.58M (90%).
| Geography | FY 2018 | FY 2020 | FY 2021 | FY 2024 |
|---|---|---|---|---|
| United States Of America | $65.40M | $434.71M | ||
| Europe | — | $47.87M | ||
| China | $3.42M | — | ||
| Total | $68.83M | $482.58M |
Legend Biotech brought in $482.58M from its two regions in fiscal 2024, the year ended December 31, 2024. Legend Biotech regrouped these regions after fiscal 2021, so the total does not compare directly with that year's $68.83M. United States Of America was the largest at $434.71M (90.1%), ahead of Europe at $47.87M (9.9%).
Legend Biotech began breaking out Europe in fiscal 2024, when it brought in $47.87M. Legend Biotech stopped reporting China as a separate region after fiscal 2021, when it brought in $3.42M.
Janssen Agreement was Legend Biotech’s largest revenue line in fiscal 2021, bringing in $65.40M of $68.80M (95%).
| Categories Of Related Parties | FY 2020 | FY 2021 |
|---|---|---|
| Janssen Agreement | $75.00M | $65.40M |
| Nanjing Probio Biotech Co., Ltd | — | $3.40M |
| Total | $75.00M | $68.80M |
Legend Biotech brought in $68.80M from its two revenue lines in fiscal 2021, the year ended December 31, 2021. Legend Biotech regrouped these revenue lines after fiscal 2020, so the total does not compare directly with that year's $75.00M. Janssen Agreement was the largest at $65.40M (95.1%), ahead of Nanjing Probio Biotech Co., Ltd at $3.40M (4.9%).
Legend Biotech began breaking out Nanjing Probio Biotech Co., Ltd in fiscal 2021, when it brought in $3.40M.
As Previously Reported was Legend Biotech’s largest revenue line in fiscal 2020, bringing in $75.68M of $75.00M (101%).
| Total Restatement Impacts | FY 2019 | FY 2020 |
|---|---|---|
| As Previously Reported | $57.26M | $75.68M |
| Total Adjustments | — | -$676.00K |
| Total | $57.26M | $75.00M |
Legend Biotech brought in $75.00M from its two revenue lines in fiscal 2020, the year ended December 31, 2020. Legend Biotech regrouped these revenue lines after fiscal 2019, so the total does not compare directly with that year's $57.26M. As Previously Reported was the largest at $75.68M (100.9%).
Legend Biotech began breaking out Total Adjustments in fiscal 2020, when it brought in -$676.00K. The total is net of Total Adjustments, which took $676.00K off revenue in fiscal 2020.
Legend Biotech (LEGN) reports its revenue by geography, by categories of related parties and by total restatement impacts. In fiscal 2024, United States Of America was its largest region, bringing in $434.71M (90.1% of the total), followed by Europe at $47.87M (9.9%).
United States Of America was Legend Biotech's largest region in fiscal 2024, bringing in $434.71M, or 90.1% of the $482.58M total across its two regions.
Janssen Agreement was Legend Biotech's largest revenue line in fiscal 2021, bringing in $65.40M, or 95.1% of the $68.80M total across its two revenue lines.
Every figure comes from Legend Biotech's annual financial filings, as reported. Each line keeps the name Legend Biotech gives it, and years follow its fiscal calendar.
Legend Biotech's revenue by geography goes back to fiscal 2018, with figures through fiscal 2024. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.